Medithings
4 known investors
MEDiThings develops an AI-based wearable device that monitors bladder activity for patients with voiding disorders, using near-infrared spectroscopy (NIRS) and biosignal analysis. The device provides real-time data analysis to support individualized treatment and improve patient quality of life.
Also known as MEDiThings Β· λ©λλ΅μ€
Investors Β· 4
Also in the syndicate Β· 3
Company profile
researched Aug 2026MEDiThings (λ©λλ΅μ€) is a South Korean healthcare technology company that develops wearable bladder monitoring devices and an accompanying artificial intelligence platform. Its device uses near-infrared light, described as harmless to the human body, to measure the volume of urine in the bladder and transmits that information to mobile phones and monitors used by patients, caregivers and medical staff. AI techniques are applied to the collected signals to detect early indications of bladder-related conditions, and the company positions the system as supporting individualized management of voiding disorders, including neurogenic bladder.
The company's product line includes a wearable bladder monitoring device referred to in Korean press coverage as MediLight (λ©λλΌμ΄νΈ). Alongside the device, MEDiThings is developing a personalized urination management platform that it plans to upgrade further. The company name combines "Medi" from Medical with "Things" from Internet of Things, reflecting IoT as a core technology, and it describes its products as IoBT (Internet of Bladder Things) wearable devices.
Founding story
The company was founded in 2020 by co-founders Professor Aram Kim and Sehwan Kim.
Business model
MEDiThings manufactures wearable bladder monitoring hardware paired with an AI-based software platform for patients, caregivers and clinicians.
Traction
The company was named one of five Grand Prize winners at the 2024 Startup Incubating Competition and has raised a Series A round from strategic and financial investors, following earlier bridge investment from Kakao Ventures and D.CAMP. Its investor base also includes SparkLabs Accelerator.
Latest developments
In June 2024, MEDiThings signed an investment agreement with Huons Medical Tech, which cited strengthening its urological device business, and closed a Series A round with new investors Huons Global, InterVest and DT&Investment. In November 2024 it was among the Grand Prize winners of the 2024 Startup Incubating Competition, and in February 2025 its MediLight wearable bladder monitoring device was covered by Korean healthcare press. The company has stated plans to set up a US entity, pursue clinical research with US universities and upgrade its personalized urination management platform.
βΈFull profile β market position, technology, go-to-market, geography
Market position
MEDiThings is a Korean digital health startup at the Series A stage in the medical devices and equipment sector, with sub-segments spanning healthcare IT, monitoring equipment and medical software, and verticals including artificial intelligence, healthtech and wearables. Korean media coverage has characterized its bladder monitoring wearable as a distinctive product in the voiding disorder category, and the company has been featured in an investor column by SparkLabs.
Technology
The core technology combines near-infrared spectroscopy (NIRS) sensing with biosignal analysis to measure urine volume in the bladder without ionizing radiation. Measurements are transmitted to mobile phones and monitoring screens accessible to patients, guardians and medical staff, and artificial intelligence models are applied to detect early signs of bladder-related disease and to support real-time, individualized treatment decisions. IoT connectivity is described by the company as a core element of its medical device platform.
Go-to-market
Patients with voiding disorders, including neurogenic bladder patients, together with their caregivers and the medical staff treating them.
Geography
Headquartered in South Korea, with Preqin listing Seoul as its location and describing the company as based in Chungcheongnam-do. The company plans to establish a US corporation and to conduct clinical research with US universities.
Compiled by commissioned research from 5 cited public sources β announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Timeline Β· 5
launches, deals, and filingsKorean healthcare outlet HIT News covered MEDiThings' wearable bladder monitoring device, MediLight.
MEDiThings was named one of five startups receiving the Grand Prize at the 2024 Startup Incubating Competition.
Korean press reported that Huons Medical Tech entered an investment contract with MEDiThings, citing reinforcement of its urological device business.
MEDiThings raised an undisclosed amount in Series A funding from new investors Huons Global, InterVest and DT&Investment to advance its AI-based bladder care solution.
The company secured bridge investment from Kakao Ventures and D.CAMP, according to press coverage listed in its newsroom.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
βΈResearch sources Β· 5
primary sources listed
- Medithingsmedithings.co.kr Β· web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Medithings do?
- MEDiThings develops a near-infrared, AI-based wearable device that monitors bladder activity in patients with voiding disorders.
- Who are Medithings's investors?
- Medithings's investors include Kakao Ventures.